Literature DB >> 10502413

The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway.

S Rao1, J Gray-Bablin, T W Herliczek, K Keyomarsi.   

Abstract

Cyclic AMP (cAMP) elevation affects growth arrest and differentiation in a wide variety of breast cell lines; however, the mechanisms associated with this process are poorly understood. Previous studies linked cAMP-mediated growth arrest in breast tumor cells to increased levels of cyclin kinase inhibitor (CKI), p21. In the present study we examined the role of cAMP-dependent protein kinase (PKA) on p21 and p27 induction in the breast cancer cell line, MDA-MB-157. The induction of the CKIs by modulators of cAMP such as cholera toxin (CT) + 1-isobutyl-3-methylxanthine (IBMX) and lovastatin fluctuates with biphasic kinetics (although the kinetics of CKI induction with CT + IBMX treatment are different from that of lovastatin) and is depicted by the periodic accumulation of lower molecular weight forms of p21 and p27 which also correlate with fluctuations in CDK2 activity. Using three different approaches we show that the cAMP-mediated induction of CKIs is independent of PKA activity. In the first approach we treated MDA-MB-157 cells with a variety of cAMP modulators such as CT + IBMX, and forskolin in the presence or absence of H-89, a potent PKA inhibitor. This analysis revealed that the cAMP activators were capable of inducing p21 even though PKA activity was completely eliminated. In the second approach PKA dominant negative stable clones of MDA-MB-157 treated with CT + IBMX or forskolin also resulted in p21 induction, in the absence of any PKA activity. Last, treatment of MDA-MB-157 cells with lovastatin, another known cAMP modulator which also causes growth arrest, resulted in the induction of p21 and p27 without any increase in PKA activity. Collectively, the above results suggest that the induction of p21 by cAMP is through a novel pathway, independent of PKA activity. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502413     DOI: 10.1006/excr.1999.4620

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

1.  Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Authors:  Banu K Arun; Yun Gong; Diane Liu; Jennifer K Litton; Angelica M Gutierrez-Barrera; J Jack Lee; Lana Vornik; Nuhad K Ibrahim; Terri Cornelison; Gabriel N Hortobagyi; Brandy M Heckman-Stoddard; Kimberly B Koenig; Ricardo R Alvarez; James L Murray; Vicente Valero; Scott M Lippman; Powel Brown; Nour Sneige
Journal:  Breast Cancer Res Treat       Date:  2016-06-10       Impact factor: 4.872

2.  Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression.

Authors:  Zhengyu Fang; Wantong Yao; Yi Xiong; Jiana Li; Li Liu; Lei Shi; Wei Zhang; Chao Zhang; Liping Nie; Jun Wan
Journal:  BMC Cancer       Date:  2011-05-24       Impact factor: 4.430

Review 3.  Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

Authors:  Arun Samidurai; Lei Xi; Anindita Das; Audra N Iness; Navin G Vigneshwar; Pin-Lan Li; Dinender K Singla; Sakthivel Muniyan; Surinder K Batra; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2021-04-22       Impact factor: 13.400

4.  Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells.

Authors:  Ae-Rang Hwang; Jung-Hwa Han; Jae Hyang Lim; Young Jin Kang; Chang-Hoon Woo
Journal:  PLoS One       Date:  2017-05-22       Impact factor: 3.240

5.  DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry.

Authors:  Kathryn Balmanno; Tracy Millar; Martin McMahon; Simon J Cook
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.